11.65 USD
-0.29 (-2.43%)
11.65 USD
0 (0%)
Taking everything into account, VREX scores 5 out of 10 in our fundamental rating. VREX was compared to 186 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of VREX get a neutral evaluation. Nothing too spectacular is happening here. VREX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
VREX had positive earnings in the past year.
VREX had a positive operating cash flow in the past year.
In multiple years VREX reported negative net income over the last 5 years.
Each year in the past 5 years VREX had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -6.35%, VREX is doing good in the industry, outperforming 65.59% of the companies in the same industry.
The Return On Equity of VREX (-14.88%) is better than 63.98% of its industry peers.
VREX has a Return On Invested Capital of 5.67%. This is in the better half of the industry: VREX outperforms 77.96% of its industry peers.
The Average Return On Invested Capital over the past 3 years for VREX is below the industry average of 8.84%.
The 3 year average ROIC (4.82%) for VREX is below the current ROIC(5.67%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.35% | ||
| ROE | -14.88% | ||
| ROIC | 5.67% |
ROA(3y)-2.14%
ROA(5y)-0.47%
ROE(3y)-5.1%
ROE(5y)-1.2%
ROIC(3y)4.82%
ROIC(5y)5.54%
1.3 Margins
Looking at the Operating Margin, with a value of 7.83%, VREX is in the better half of the industry, outperforming 75.27% of the companies in the same industry.
VREX's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 34.40%, VREX is doing worse than 73.66% of the companies in the same industry.
In the last couple of years the Gross Margin of VREX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.83% | ||
| PM (TTM) | N/A | ||
| GM | 34.4% |
OM growth 3Y-8.19%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y5.76%
2. Health
2.1 Basic Checks
VREX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
VREX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VREX has been increased compared to 5 years ago.
The debt/assets ratio for VREX has been reduced compared to a year ago.
2.2 Solvency
VREX has an Altman-Z score of 1.90. This is not the best score and indicates that VREX is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of VREX (1.90) is better than 60.75% of its industry peers.
The Debt to FCF ratio of VREX is 19.87, which is on the high side as it means it would take VREX, 19.87 years of fcf income to pay off all of its debts.
VREX's Debt to FCF ratio of 19.87 is fine compared to the rest of the industry. VREX outperforms 70.97% of its industry peers.
A Debt/Equity ratio of 0.79 indicates that VREX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.79, VREX is doing worse than 69.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 19.87 | ||
| Altman-Z | 1.9 |
ROIC/WACC0.76
WACC7.51%
2.3 Liquidity
VREX has a Current Ratio of 3.43. This indicates that VREX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.43, VREX is doing good in the industry, outperforming 61.29% of the companies in the same industry.
A Quick Ratio of 1.83 indicates that VREX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.83, VREX is in line with its industry, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.43 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
VREX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.00%, which is quite impressive.
VREX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 57.78% yearly.
Looking at the last year, VREX shows a small growth in Revenue. The Revenue has grown by 4.14% in the last year.
The Revenue has been growing slightly by 2.73% on average over the past years.
EPS 1Y (TTM)60%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%94.74%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y-0.58%
Revenue growth 5Y2.73%
Sales Q2Q%11.28%
3.2 Future
VREX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.66% yearly.
Based on estimates for the next years, VREX will show a small growth in Revenue. The Revenue will grow by 4.03% on average per year.
EPS Next Y-0.32%
EPS Next 2Y7.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.92%
Revenue Next 2Y4.03%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.24 indicates a correct valuation of VREX.
VREX's Price/Earnings ratio is rather cheap when compared to the industry. VREX is cheaper than 89.78% of the companies in the same industry.
VREX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.51.
A Price/Forward Earnings ratio of 13.28 indicates a correct valuation of VREX.
90.32% of the companies in the same industry are more expensive than VREX, based on the Price/Forward Earnings ratio.
VREX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.24 | ||
| Fwd PE | 13.28 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VREX is valued cheaper than 95.70% of the companies in the same industry.
VREX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VREX is cheaper than 83.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.84 | ||
| EV/EBITDA | 7.44 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.23
EPS Next 2Y7.66%
EPS Next 3YN/A
5. Dividend
5.1 Amount
VREX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
11.65
-0.29 (-2.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners96.22%
Inst Owner Change2.62%
Ins Owners1.65%
Ins Owner Change9.46%
Market Cap485.81M
Revenue(TTM)844.60M
Net Income(TTM)-70.30M
Analysts83.64
Price Target17.54 (50.56%)
Short Float %2.25%
Short Ratio3.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)251.48%
Min EPS beat(2)98.76%
Max EPS beat(2)404.2%
EPS beat(4)4
Avg EPS beat(4)167.83%
Min EPS beat(4)81.21%
Max EPS beat(4)404.2%
EPS beat(8)5
Avg EPS beat(8)85.78%
EPS beat(12)9
Avg EPS beat(12)64.21%
EPS beat(16)12
Avg EPS beat(16)54.96%
Revenue beat(2)2
Avg Revenue beat(2)3.46%
Min Revenue beat(2)2.35%
Max Revenue beat(2)4.57%
Revenue beat(4)3
Avg Revenue beat(4)1.33%
Min Revenue beat(4)-3.1%
Max Revenue beat(4)4.57%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)5
Avg Revenue beat(12)-0.02%
Revenue beat(16)8
Avg Revenue beat(16)-0.05%
PT rev (1m)-3.37%
PT rev (3m)-1.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.05%
EPS NY rev (1m)7%
EPS NY rev (3m)-11.79%
Revenue NQ rev (1m)0.36%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)0.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.24 | ||
| Fwd PE | 13.28 | ||
| P/S | 0.58 | ||
| P/FCF | 25.84 | ||
| P/OCF | 11.65 | ||
| P/B | 1.03 | ||
| P/tB | 1.87 | ||
| EV/EBITDA | 7.44 |
EPS(TTM)0.88
EY7.55%
EPS(NY)0.88
Fwd EY7.53%
FCF(TTM)0.45
FCFY3.87%
OCF(TTM)1
OCFY8.58%
SpS20.25
BVpS11.33
TBVpS6.24
PEG (NY)N/A
PEG (5Y)0.23
Graham Number14.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.35% | ||
| ROE | -14.88% | ||
| ROCE | 7.18% | ||
| ROIC | 5.67% | ||
| ROICexc | 6.83% | ||
| ROICexgc | 9.45% | ||
| OM | 7.83% | ||
| PM (TTM) | N/A | ||
| GM | 34.4% | ||
| FCFM | 2.23% |
ROA(3y)-2.14%
ROA(5y)-0.47%
ROE(3y)-5.1%
ROE(5y)-1.2%
ROIC(3y)4.82%
ROIC(5y)5.54%
ROICexc(3y)5.86%
ROICexc(5y)6.54%
ROICexgc(3y)8.71%
ROICexgc(5y)10.09%
ROCE(3y)6.1%
ROCE(5y)7.01%
ROICexgc growth 3Y-6.75%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.38%
ROICexc growth 5YN/A
OM growth 3Y-8.19%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y5.76%
F-Score5
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 19.87 | ||
| Debt/EBITDA | 3.98 | ||
| Cap/Depr | 84.19% | ||
| Cap/Sales | 2.71% | ||
| Interest Coverage | 2.11 | ||
| Cash Conversion | 44.69% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.43 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 1.9 |
F-Score5
WACC7.51%
ROIC/WACC0.76
Cap/Depr(3y)77.68%
Cap/Depr(5y)67.38%
Cap/Sales(3y)2.78%
Cap/Sales(5y)2.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%94.74%
EPS Next Y-0.32%
EPS Next 2Y7.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.14%
Revenue growth 3Y-0.58%
Revenue growth 5Y2.73%
Sales Q2Q%11.28%
Revenue Next Year3.92%
Revenue Next 2Y4.03%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y105.28%
EBIT growth 3Y-8.72%
EBIT growth 5YN/A
EBIT Next Year55.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.84%
OCF growth 3Y35.13%
OCF growth 5Y25.87%
VAREX IMAGING CORP / VREX FAQ
What is the fundamental rating for VREX stock?
ChartMill assigns a fundamental rating of 5 / 10 to VREX.
What is the valuation status of VAREX IMAGING CORP (VREX) stock?
ChartMill assigns a valuation rating of 6 / 10 to VAREX IMAGING CORP (VREX). This can be considered as Fairly Valued.
What is the profitability of VREX stock?
VAREX IMAGING CORP (VREX) has a profitability rating of 5 / 10.
How financially healthy is VAREX IMAGING CORP?
The financial health rating of VAREX IMAGING CORP (VREX) is 4 / 10.
What is the expected EPS growth for VAREX IMAGING CORP (VREX) stock?
The Earnings per Share (EPS) of VAREX IMAGING CORP (VREX) is expected to decline by -0.32% in the next year.